Skip to main content
. Author manuscript; available in PMC: 2015 Oct 28.
Published in final edited form as: Cancer Lett. 2014 Jul 24;353(2):281–289. doi: 10.1016/j.canlet.2014.07.032

Figure 3. Enhanced sensitivity of MiaPaCa-2-luc tumors to treatment with FAK inhibitor C10.

Figure 3

Mice (n = 6-10 per group) were inoculated with MiaPaCa-2-luc or BxPC3 pancreatic cancer cells. Vehicle (PBS) or C10 at 20 mg/kg were administered intraperitoneally (IP) once daily for five days a week. (A) MiaPaCa-2-luc or (D) BxPC3 tumor volumes were measured over the course of the study and values represent mean ± S.E.M *p < 0.05. Percent reduction in tumor volume relative to the vehicle-treated group was calculated using the tumor size measurements on the last day of the study. (B) MiaPaCa-2-luc or (E) BxPC3 tumor weights were recorded at the end of the treatment protocol. Error bars represent mean ± S.D. *p <0.05. Body weights of mice bearing (C) MiaPaCa-2-luc or (F) BxPC3 tumors were analyzed to evaluate tolerability to C10-treatment. No statistically significant difference in body weights was observed between the two treatment arms.